

Special Issue

Marine Molecules for the Treatment of Thrombosis

Message from the Guest Editor

According to the World Health Organization, the formation of thrombi is one of the leading causes of death in modern life. Current antithrombotic treatments suffer from potential secondary effects or increase the health care costs because of a necessary control of the coagulation levels for vitamin K antagonists or of the high production costs for recent synthetic thrombin and factor Xa inhibitors. For these reasons, marine molecules are being screened for anticoagulants. The best known marine anticoagulants are sulphated polysaccharides: fucoidans and carrageenans from algae; fucosylated chondroitin sulphates, sulfated fucans, and galactans from algae, ascidians, sea cucumbers, and urchins; heparins and heparan sulfate hybrids found in molluscs, crustaceans, ascidians, and urchins. However, other less renowned marine molecules present interesting prospects: anticoagulant peptides (from blood-sucking worms and bacteria and sponges), fibrinolytic enzymes (from algae and bacteria), anticoagulant terpenes and sphingosines (from algae and sponges). The aim of this Special Issue is to recapitulate the current knowledge and publish novel articles on marine antithrombotic molecules.


Guest Editor

Dr. Ramon Novoa Carballal

3B's Research Group – Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, 4805-017, Barco, Guimarães, Portugal

Deadline for manuscript submissions

closed (31 August 2020)



Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



mdpi.com/si/21561

Marine Drugs
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
marinedrugs@mdpi.com

[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)





Marine Drugs

an Open Access Journal
by MDPI

Impact Factor 5.4
CiteScore 10.1
Indexed in PubMed



[mdpi.com/journal/
marinedrugs](https://mdpi.com/journal/marinedrugs)



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))